MustGrow Biologics More Than Triples Financing To $6.9 Million Due To Demand
Demand within the natural biopesticide space from investors appears to be extremely strong. MustGrow Biologics (CSE: MGRO) this morning expanded its previously announced $2.0 million private placement rather significantly, with the offering now pegged at $6.9 million.
The financing will now see a total of roughly 2.7 million units sold, at a price of $2.60 per unit. Each unit contains one common share and one full warrant, with warrants valid for a period of two years and pegged at $4.00 per share.
Notably, Ira Gluskin and related parties have agreed to invest $1.0 million into the financing, under the same terms and conditions. Gluskin most notably is the co-founder of Gluskin Sheff + Associates, a major wealth management firm, while also serving as a director for a number of advisory committees.
The financing will see proceeds utilized for the development of its pipeline as well as for working capital and general corporate purposes.
The offering is currently slated to close October 6.
MustGrow Biologics last traded at $2.87 on the CSE.
FULL DISCLOSURE: MustGrow Biologics Corp is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover MustGrow Biologics Corp on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.
As the founder of The Deep Dive, Jay is focused on all aspects of the firm. This includes operations, as well as acting as the primary writer for The Deep Dive’s stock analysis. In addition to The Deep Dive, Jay performs freelance writing for a number of firms and has been published on Stockhouse.com and CannaInvestor Magazine among others.
